The Stool Softeners Market is estimated to witness stupendous growth in the years to come. AI is already into the disruption mode regarding the healthcare vertical. Machine learning is used for displaying the relevant info about health in the mobile app. The application of AI in healthcare is better known as “Augmented Intelligence”. This would be the running trend in the healthcare vertical in the upcoming period.
Stool Softeners: Overview
According to the latest research by PMR, stool softeners is set to witness a 7.0 % growth during the year 2021-2031. Stool softeners are a category of laxatives with uses related to prevention of constipation and to soften hard stools. They are called emollient laxatives and the main active ingredients comprise of docusate sodium and docusate calcium.
The stool softeners are advised for short-term or temporary use for patients with constipation, suffering from hemorrhoids, heart diseases and other disorders which require interception of straining during bowel movements. The prevalence of constipation is fairly common in hospitalized patients and patients in outpatient clinics.
To remain ‘ahead’ of your competitors, request for a sample @
According to the American Gastroenterological Association, the prevalence of constipation is 16% in all adults and about 33.5% is attributed to population older than 60 years.
Who are the Key Manufacturers and Suppliers of Stool Softeners?
The key companies operating in manufacturing and supply of stool softeners include
- AstraZeneca plc
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Abbott Laboratories
- Aristo Pharmaceuticals Ltd.
- Mallinckrodt Plc.
- Hunan Warant Chiral Pharmaceutical
- Boehringer Ingelheim GmbH
- Takeda Pharmaceutical Company Ltd
- Raptakos Brett & Co. Ltd.
- Mylan N.V.
Get a Customized Scope to Match Your Need Ask an Expert- email@example.com
What is Driving Demand for Stool Softeners?
The demand for stool softeners is largely associated with the increasing incidence of constipation. Geriatric patients present a widespread presence of cases of constipation as compared to the younger population. This is due to the lack of physical activity, lack of proper diet, consumption of low-fiber foods, presence of illness and the use of prescribed drugs, which leads to a rise in demand of stool softeners in this population group.
The prevalence rate of constipation is reported to be between 11%-38%, according to the National Institute for Clinical Excellence. Constipation due to pregnancy, and menopausal cases with fluctuations of hormonal levels has also boosted the use of stool softeners globally.
Furthermore, eating disorders sedentary lifestyle, stress, inadequate fluid intake and endocrine or metabolic disorders among many other factors are responsible for the uptake of stool softeners to administer relief over a short-term phase of use.
Pre-Book Right Now for Exclusive Analyst Support @
Which factors are likely to augment growth of Stool Softeners?
The most critical augmentative factor in the growth of demand in stool softeners is the increasing prevalence of ailments such as diabetes, anorectal disorders and hypothyroidism. According to a review in the Neurogastroenterology and Motility Journal, the effect on autonomic nerves of the colon due to changes in the vagus nerve in patients with diabetes mellitus results in constipation.
This factor has enhanced the growth of administration of stool softeners for patients with constipation associated with diabetes and other inadequacies including neurological disorders.
About Us: – Persistence Market Research
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – firstname.lastname@example.org
Website – https://www.persistencemarketresearch.com